Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 3, 2014, Pages 325-329

  Barnea, Y ^a   Navon Venezia, S ^a   Kuzmenko, B ^a   Artzi, N ^a   Carmeli, Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE MEDOCARIL; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; TOBRAMYCIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COUNT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; MALE; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; STERNOTOMY; STERNUM; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; MALE; MEDIASTINITIS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RATS; STAPHYLOCOCCAL INFECTIONS; STERNUM;

EID: 84896726413     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1959-9     Document Type: Article

References (22)

1. National Nosocomial Infections Surveillance System (2002) National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 30:458-475
2. Milano CA, Kesler K, Archibald N et al (1995) Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 92:2245-2251
3. Kappstein I, Schulgen G, Fraedrich G et al (1992) Added hospital stay due to wound infections following cardiac surgery. Thorac Cardiovasc Surg 40:148-151
4. Asensio A, Torres J (1999) Quantifying excess length of postoperative stay attributable to infections: a comparison of methods. J Clin Epidemiol 52:1249-1256
5. Hollenbeak CS, Murphy D, Dunagan WC et al (2002) Nonrandom selection and the attributable cost of surgical-site infections. Infect Control Hosp Epidemiol 23:177-182
6. Jenney AW, Harrington GA, Russo PL et al (2001) Cost of surgical site infections following coronary artery bypass surgery. ANZ J Surg 71:662-664
7. Sharma M, Berriel-Cass D, Baran J Jr (2004) Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol 25:468-471
8. Fowler VG Jr, Kaye KS, Simel DL et al (2003) Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitis. Circulation 108:73-78
9. Tammelin A, Hambraeus A, Ståhle E (2002) Mediastinitis after cardiac surgery: improvement of bacteriological diagnosis by use of multiple tissue samples and strain typing. J Clin Microbiol 40:2936-2941
10. Muñoz P, Menasalvas A, Bernaldo de Quirós JC et al (1997) Postsurgical mediastinitis: a case-control study. Clin Infect Dis 25:1060-1064
11. Jakob HG, Borneff-Lipp M, Bach A et al (2000) The endogenous pathway is a major route for deep sternal wound infection. Eur J Cardiothorac Surg 17:154-160
12. Dodds Ashley ES, Carroll DN, Engemann JJ et al (2004) Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 38:1555-1560
13. Braxton JH, Marrin CA, McGrath PD et al; Northern New England Cardiovascular Disease Study Group (2000) Mediastinitis and long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg 70:2004-2007
14. Micek ST (2007) Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45:S184-S190
15. Page MG (2006) Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 6:480-485
16. Hebeisen P, Heinze-Krauss I, Angehrn P et al (2001) In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45:825-836
17. Entenza JM, Hohl P, Heinze-Krauss I et al (2002) BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 46:171-177
18. Vaudaux P, Gjinovci A, Bento M et al (2005) Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:3789-3793
19. Davies TA, Page MG, Shang W et al (2007) Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51:2621-2624
20. Yin LY, Calhoun JH, Thomas JK et al (2008) Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52:1618-1622
21. Tattevin P, Basuino L, Bauer D et al (2010) Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:610-613
22. Barnea Y, Carmeli Y, Kuzmenko B et al (2008) Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. J Antimicrob Chemother 62:1339-1343